Apros Therapeutics, Inc.

Delivering innate immune agonists specifically to the right tissue, for the right duration, at the right dose to fight cancer and infectious disease. Apros Therapeutics is a drug discovery and development company focused on tissue-targeted small molecule innate immune agonists to increase tumor immunogenicity – turning cold tumors hot. Combining TLR agonists with checkpoint inhibitors provides complementary mechanisms to boost the tumor immunity cycle and to improve the response of current cancer immune therapies. Ding has pioneered on developing and applying innovative chemical approaches to stem cell biology and regeneration, with a focus on discovering and characterizing novel small molecules that can control various cell fate/function, including stem cell maintenance, activation, differentiation and reprogramming in various developmental stages and tissues. Ding is a cofounder of several biotechnology companies.